We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.
- Authors
Wild, Damian; Wicki, Andreas; Mansi, Rosalba; Béhé, Martin; Keil, Boris; Bernhardt, Peter; Christofori, Gerhard; Ell, Peter J; Mäcke, Helmut R
- Abstract
Strong overexpression of glucagonlike peptide-1 (GLP-1) receptors in human insulinoma provides an attractive target for imaging. The first clinical trials demonstrated that GLP-1 receptor SPECT/CT using [Lys(40)(Ahx [6-aminohexanoic acid]-DOTA-(111)In)NH(2)]-exendin-4 can localize hardly detectable insulinomas. However, [Lys(40)(Ahx-DOTA-(111)In)NH(2)]-exendin-4 imaging has drawbacks related to the use of (111)In in that it is costly and carries a relatively high radiation burden for the patient. The aim of this study was the preclinical evaluation of [Lys(40)(Ahx-DOTA-(68)Ga)NH(2)]-exendin-4 for PET/CT and [Lys(40)(Ahx-hydrazinonicotinamide [HYNIC]-(99m)Tc)NH(2)]-exendin-4 for SPECT/CT.
- Publication
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010, Vol 51, Issue 7, p1059
- ISSN
1535-5667
- Publication type
Journal Article
- DOI
10.2967/jnumed.110.074914